Track topics on Twitter Track topics that are important to you
Eli Lilly and Company announced Friday that its new drug for acute migraines, lasmiditan, has met its primary endpoint in a second Phase 3 study and the company plans to submit for FDA approval during the second half of 2018.
Original Article: Eli Lilly's new migraine drug succeeds in late-stage studyNEXT ARTICLE
The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...